BioPharmSignal logoBioPharmSignal

Biotech News

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics (TNYA)Tenaya TherapeuticsClinical readout

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing SOUTH

Related news

TNYATenaya Therapeutics2026-06-02 20:30 EST

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

TNYATenaya Therapeutics2025-12-11 21:01 EST

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

View all latest news

Tenaya Therapeutics

Genetically Informed Cardiac Therapies Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease. TN-201 TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in...

Recent company news

TNYATenaya Therapeutics2026-08-05 20:05 EST

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

TNYATenaya Therapeutics2026-08-04 20:05 EST

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

TNYATenaya Therapeutics2026-07-15 01:00 EST

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

TNYATenaya Therapeutics2026-06-29 12:30 EST

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

TNYATenaya Therapeutics2026-06-03 11:00 EST

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Stock data

Close
0.70 USD
Market cap
171.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States